HTG Board of Directors
High Throughput Genomics Board of Directors.
Harry A. George
Chairman
Mr. George has more than 27 years of experience with successful rapid growth technology-related companies, serving as founder, operating officer, or investor.
From 1981 to 1989, Mr. George was co-founder, director, and vice-president of finance for Interleaf, a pioneer in electronic publishing. Prior to that, he was co-founder, director and vice-president of finance of Kurzwell Computer Products. Currently, he is co-founder of Solstice Capital.
Currently serving on: the Board of Directors for: Lumidigm, High Throughput Genomics (HTG), CellzDirect, Regenesis Biomedical and AmpliMed. Other positions: Member of Investors’ Circle, member of the conference screening panel of the Arizona Venture Capital Conference (1997-2003), member of the advisory committee of the MBA program at the University of Arizona, Eller School of Business, advisor to the Arizona Center for Innovation, Trustee of the Arizona-Sonoma Desert Museum and the Tucson Museum of Art, Vice-Chair of Treasure the Desert Capital Campaign.
Donald Grimm
Mr. Grimm’s distinguished career at Eli Lily & Company included a variety of key management positions in the company’s pharmaceutical, biotechnological and medical device businesses. He served as Director of Worldwide Pharmaceutical Pricing, Director of Pharmaceutical Market Research, Director of West Coast Pharmaceutical Sales, and President/CEO and Chairman of Hybritech, Inc. While at Lily’s Hybritech, he orchestrated the development of Prostate Specific Antigen (PSA), the most significant new cancer diagnostic test ever developed for men. The company’s increased from $50 million to $150 million under Mr. Grimm’s leadership.
Other positions of responsibility have included:
Chairman, Pacific Biotech (a Lily company)
V.P. Medical Devices & Diagnostics, Eli Lily & Company
CEO, Board of Directors, Telios Pharmaceuticals
Chairman, President, Founder, Strategic Design (1994 – current)
West Coast Managing Director, Copenhagen Capacity
Chairman, San Diego Mayor’s Task Force on Effectiveness and Efficiency in City Government
Chairman, San Diego County Economic Advisory Board
Mr. Grimm currently sits on the Board of Directors for: Invitrogen, Aegis, Angstrom, ATI, CellzDirect, Q3DM, Green Cancer Center at Scripps Clinic, the UCSD Cancer Center Foundation, the Advisory Board of Scripps Clinic, University of Pittsburgh School of Pharmacy Board of Visitors, Limbaugh Center of the University of Pittsburgh.
Bruce E. Seligmann, Ph.D.
Founder and Chief Science Officer
An internationally recognized scientist, Dr. Bruce Seligmann began his scientific career at the NIH-NIAID, Laboratory of Clinical Investigation, and then joined Ciba-Geigy (Novartis). There he led the drug discovery programs within the Department of Molecular Biology, Inflammation, and Osteoarthritis Research. He went on to join the start-up biotech company, Selectide, where as V.P. of R&D, Dr. Seligmann initiated the development of non-peptide small molecule combinatorial chemistry (combichem). He established drug discovery programs and selected compounds which produced a novel Factor Xa drug that advanced into clinical trials. After serving as Center Director upon the acquisition of Selectide by MMD (Aventis), Dr. Seligmann went on to found both SIDDCO and HTG, which developed and markets the quantitative Nuclease Protection Assay (qNPA™). As one of the inventors and developers of the intellectual property forming the basis of the ArrayPlate and qNPA™ technology, Dr. Seligmann’s vision is to provide this time and cost saving technology to assist the advancement of research, drug discovery and the development of better therapies and diagnostics, which ultimately provides better patient care and quality of life.
His philosophy is better tools mean better research, better research means better results, and better results mean better patient outcomes.
Alan Smith
Mr. Smith is the CFO of SEBRA Corporation, a world leader in producing precision instruments for blood banks, catheter manufacturers, biotechnology companies and medical device manufacturers. He worked with Deloitte & Touche for 24 years, including the position of Partner in D&T’s New York headquarters and Partner in Charge of the company’s Tucson office, before joining SEBRA in 1991. He brings experience in accounting, auditing and management to the HTG Board of Directors.
Jeff Tarlowe
Mr. Tarlowe is CFO and co-founder of Merck Capital Ventures, LLC, (MCV) a subsidiary of the global pharmaceutical company, Merck & Co., Inc. Founded in 2000, MCV seeks to invest capital in private, emerging businesses focused in areas related to the discovery, development, manufacturing and marketing of pharmaceuticals and other health care services. The firm invests in companies with enabling technologies whose goal is to improve productivity across all operational areas within the biopharmaceutical industry. MCV’s existing investment portfolio includes High Throughput Genomics, Acurian, PHT, Aegis Analytical, ImpactRx, MedCases/IC Axon, Cytel, VisEn Medical and NanoImaging Services.
Mr. Tarlowe has served more than 20 years at Merck in a variety of important management positions.Most recently, he led the Financial Evaluations group at Medco Health in the late 1990’s while it was a subsidiary of Merck.Previously, he held numerous roles in the Merck organization supporting mergers and acquisitions, investment and debt planning, project evaluation, capital structure optimization, foreign exchange management and pharmaceutical industry economics.
Mr. Tarlowe received an MBA in Finance from Columbia Business School, where he was elected to Beta Gamma Sigma Honor Society for business students, and a BA in mathematics, cum laude, from Pomona College. Mr. Tarlowe currently serves as director for the Boards of High Throughput Genomics and Acurian, and has observer status on the Boards of other MCV portfolio companies.
Tim (TJ) Johnson
Chief Executive Officer
Tim (TJ) Johnson, an accomplished management executive, joins HTG from LVC Consulting, where he was a partner with the firm. Previously, he was senior vice president of global business services at Ventana Medical Systems. During his five years at Ventana, Johnson held various senior management positions of increasing responsibility.
Prior to Ventana Medical Systems, Johnson was vice president of global marketing at Hill-Rom Company a subsidiary of Hillenbrand Industries. With Hill-Rom Johnson also served as VP/GM of Hill-Rom Airshields, handled North American operations, and lead the global strategic planning team. He has also served as a senior consulting manager at Price Waterhouse and has sales and operational experience at Batesville Casket Company, Caloric Corporation and Frito-Lay. Johnson earned a B.S. in business from Indiana University.
